{"filing":{"accession_number":"0001654954-26-007988","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-09-01","report_date":"2026-09-01","primary_document":"a7296s.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426007988/a7296s.htm"},"events":[{"id":30780,"run_id":28218,"accession_number":"0001654954-26-007988","anchor_item_number":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"AstraZeneca announced the appointment of Wan Ling Martello as a Non-Executive Director effective 1 September 2026, with membership on the Audit Committee. This is a clear executive appointment to the board of a major pharmaceutical company, and the disclosure includes biographical details and a statement from the Chair endorsing her qualifications. Board appointments at large-cap public companies are material to investors assessing governance and oversight.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-01","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":33488,"accession_number":"0001654954-26-007988","item_number":null,"item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"AstraZeneca announced the appointment of Wan Ling Martello as a Non-Executive Director effective 1 September 2026, with membership on the Audit Committee. This is a clear executive appointment to the board of a major pharmaceutical company, and the disclosure includes biographical details and a statement from the Chair endorsing her qualifications. Board appointments at large-cap public companies are material to investors assessing governance and oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-01T11:19:36.631064+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-01"}]}